Feedback

Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database

Affiliation
Eye Institute & Affiliated Xiamen Eye Center ,School of Medicine ,Xiamen University ,Xiamen ,Fujian ,China
Li, Xiang;
Affiliation
Eye Institute & Affiliated Xiamen Eye Center ,School of Medicine ,Xiamen University ,Xiamen ,Fujian ,China
Wang, Shu Wen;
Affiliation
Eye Institute & Affiliated Xiamen Eye Center ,School of Medicine ,Xiamen University ,Xiamen ,Fujian ,China
Zhang, Zhi-Jie;
Affiliation
Shanghai Pudong Hospital ,Fudan University Pudong Medical Center ,Shanghai ,China
Luo, Zhan Yang;
Affiliation
Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area ,Chongqing Three Gorges Medical College ,Wan Zhou ,China
Tang, Jia Feng;
Affiliation
Eye Institute & Affiliated Xiamen Eye Center ,School of Medicine ,Xiamen University ,Xiamen ,Fujian ,China
Tao, Tao

Objective Although numerous drugs have been associated with cataracts, the risk for most drugs remains unclear. This study aimed to investigate the risk factors for drug-induced cataracts by analyzing large-scale data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods We used the reporting odds ratio (ROR) to evaluate reports of drug-induced cataracts in FAERS from the first quarter of 2004 to the third quarter of 2024. A univariate analysis, LASSO (least absolute shrinkage and selection operator) regression, and a multivariate regression analysis were performed to identify drug-related risk factors for cataracts, and Bonferroni correction was applied for multiple comparisons. Results Multivariate logistic regression ultimately identified 15 drugs as independent risk factors, including immunomodulators (6/15), antineoplastic drugs (3/15), psychotropic drugs (1/15), respiratory drugs (1/15), gastrointestinal drugs (1/15), orthopedic drugs (1/15), metabolic regulators (1/15), and ophthalmic drugs (1/15). The median time to onset of drug-induced cataracts was 449 days (interquartile range [IQR]: 150–901 days), with approximately 75% of adverse events occurring within 747 days. Conclusion These findings may help clinicians detect drug-related cataracts at an early stage and provide valuable insights for future research on the mechanisms of drug-induced cataracts.

Graphical Abstract

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Li, Wang, Zhang, Luo, Tang and Tao.

Use and reproduction: